Tomiya N, Watanabe K, Awaya J, Kurono M, Fujii S
FEBS Lett. 1985 Nov 25;193(1):44-8. doi: 10.1016/0014-5793(85)80076-4.
Acyl-plasmin-streptokinase complex has advantages as a 'site' directed fibrinolytic agent with the active site protected from the plasma protease inhibitors. But, in clinical use, the fibrinolytic potential of this acyl-enzyme complex is modified or abolished by the presence of streptokinase antibodies in the patients. Therefore, better therapeutic agents are required. In this work, chemical modification of the acyl-plasmin-streptokinase complex with polyethylene glycol was found to result in marked resistance to neutralization with streptokinase antibodies.
酰基纤溶酶 - 链激酶复合物作为一种“位点”导向的纤溶酶原激活剂具有优势，其活性位点受到血浆蛋白酶抑制剂的保护。但是，在临床应用中，患者体内存在的链激酶抗体可改变或消除这种酰基酶复合物的纤溶潜力。因此，需要更好的治疗药物。在这项研究中，发现用聚乙二醇对酰基纤溶酶 - 链激酶复合物进行化学修饰可使其对链激酶抗体的中和作用产生显著抗性。
